Close Menu

NEW YORK – Veracyte reported after the close of the market Tuesday that its second quarter 2019 revenues grew 32 percent year over year. 

For the three months ended June 30, the genomic testing firm reported total revenues of $30.1 million compared to $22.8 million in Q2 2018, beating analysts' average estimate of $28.9 million. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.